The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
While SIMPLE IRAs are in some ways similar to their cousins, traditional and Roth IRAs, they also share some features with workplace retirement plans such as 401(k)s. Understanding your plan's rules ...
Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results